Istaroxime

Drug Profile

Istaroxime

Alternative Names: Debio 0614; PST 2744; ST 2744

Latest Information Update: 30 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sigma-tau SpA
  • Developer CVie Therapeutics
  • Class Amines; Androstanols; Cardiotonics; Heart failure therapies; Ketosteroids; Oximes; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Decompensated heart failure

Most Recent Events

  • 30 Jan 2018 Istaroxime is still in phase II trials for Decompensated heart failure in China and Italy (NCT02617446; EudraCT2013-000540-26)
  • 05 Aug 2016 CVie Therapeutics and ScinoPharm agree to co-develop istaroxime in Taiwan for Chronic heart failure
  • 17 Aug 2015 Phase-II development is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top